CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition
Open Access
- 26 April 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Abstract
Chimeric antigen receptor (CAR)-T cell therapy for solid tumors faces significant hurdles, including T-cell inhibition mediated by the PD-1/PD-L1 axis. The effects of disrupting this pathway on T-cells are being actively explored and controversial outcomes have been reported. Here, we hypothesize that CAR-antigen affinity may be a key factor modulating T-cell susceptibility towards the PD-1/PD-L1 axis. We systematically interrogate CAR-T cells targeting HER2 with either low (LA) or high affinity (HA) in various preclinical models. Our results reveal an increased sensitivity of LA CAR-T cells to PD-L1-mediated inhibition when compared to their HA counterparts by using in vitro models of tumor cell lines and supported lipid bilayers modified to display varying PD-L1 densities. CRISPR/Cas9-mediated knockout (KO) of PD-1 enhances LA CAR-T cell cytokine secretion and polyfunctionality in vitro and antitumor effect in vivo and results in the downregulation of gene signatures related to T-cell exhaustion. By contrast, HA CAR-T cell features remain unaffected following PD-1 KO. This behavior holds true for CD28 and ICOS but not 4-1BB co-stimulated CAR-T cells, which are less sensitive to PD-L1 inhibition albeit targeting the antigen with LA. Our findings may inform CAR-T therapies involving disruption of PD-1/PD-L1 pathway tailored in particular for effective treatment of solid tumors.Keywords
All Related Versions
This publication has 66 references indexed in Scilit:
- Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology2023
- Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCCHepatology, 2021
- An NK-like CAR T cell transition in CAR T cell dysfunctionCell, 2021
- Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors2019
- Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic InstitutionsMolecular Therapy - Methods & Clinical Development, 2019
- CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functionsCancer Immunology, Immunotherapy, 2018
- Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cellsCytotherapy, 2018
- CRISPR-Cas9-mediated multiplex gene editing in CAR-T cellsCell Research, 2016
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T CellsCancer Cell, 2015
- Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral InfectionImmunity, 2007